RIPK1 and B-cell non-Hodgkin lymphoma: These results indicate that 1) HOI treatment inhibits cell proliferation of B-cell lymphoma largely via targeting RIPK1; 2) restoration of RIPK1 by small molecule inhibitors can efficiently promote cell death of B-cell lymphoma.